Lonza agrees to buy 5 Merck KGaA facilities to accelerate US expansion

Coverage, in order

1. 8d ago
   
   first Pharma Manufacturing obscure

   Lonza to acquire five CDMO sites from Merck KGaA, more than doubling US footprint

   The facilities will expand Lonza’s clinical through commercial capabilities in antibody-drug conjugates, viral vectors for cell and gene therapies, and drug delivery.

2. 8d ago
   BioSpace indie

   Lonza agrees to buy 5 Merck KGaA facilities to accelerate US expansion

   The Swiss contract development and manufacturing organization will more than double its U.S. footprint by acquiring the Merck KGaA plants.

3. 7d ago
   GEN Genetic Engineering News indie

   Lonza Expanding U.S. CDMO Footprint with Purchase of Five Merck KGaA Sites

   Lonza plans to more than double its U.S. footprint of contract development and manufacturing organization (CDMO) sites by agreeing to acquire five such sites in the U.S. from Merck KGaA, Darmstadt, Germany, in a deal the companies would only say was valued “in the low- to mid-triple-digit millions…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.